Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants

References

• Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol. 2005;3:591–600.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Watanabe S, Maher EA, et al. Pandemic potential of avian influenza A (H7N9) viruses. Trends Microbiol. 2014;22:623–631.
   PubMed Web of Science ®Google Scholar
• Zhao H, To KKW, Chu H, et al. Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza. Nat Commun. 2018;9:2358.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379:913–923.
   PubMed Web of Science ®Google Scholar
• Chai N, Swem LR, Reichelt M, et al. Two escape mechanisms of influenza a virus to a broadly neutralizing stalk-binding antibody. PLoS Pathog. 2016;12:e1005702.
   PubMed Web of Science ®Google Scholar
• Wu NC, Thompson AJ, Lee JM, et al. Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses. Science. 2020;368:1335–1340.
   PubMed Web of Science ®Google Scholar
• Zheng X, Wang H, Su Z, et al. Co-infection of SARS-CoV-2 and influenza virus in early stage of the COVID-19 epidemic in Wuhan, China. J Infect. 2020;81:e128–e129.
   PubMed Web of Science ®Google Scholar
• Cuadrado-Payán E, Montagud-Marrahi E, Torres-Elorza M, et al. SARS-CoV-2 and influenza virus co-infection. Lancet. 2020;395:e84.
   PubMed Web of Science ®Google Scholar
• Zhang AJ, Lee ACY, Chan JFW, et al. Co-infection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1)pdm09 virus enhances the severity of pneumonia in golden Syrian hamsters. Clin Infect Dis. 2021;72(e)978-e992.
   Google Scholar
• Holthausen DJ, Lee SH, Kumar VT, et al. An amphibian host defense peptide is virucidal for human H1 hemagglutinin-bearing influenza viruses. Immunity. 2017;46:587–595.
   PubMed Web of Science ®Google Scholar
• Leikina E, Delanoe-Ayari H, Melikov K, et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol. 2005;6:995–1001.
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhou J, Zhang K, et al. A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep. 2016;6:22008.
   PubMed Web of Science ®Google Scholar
• Zhao H, To KKW, Sze K-H, et al. A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2. Nat Commun. 2020;11:4252.
   PubMed Web of Science ®Google Scholar
• Lu L, Liu Q, Zhu Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhao L, Xia S, et al. De novo design of α-helical lipopeptides targeting viral fusion proteins: a promising strategy for relatively broad-spectrum antiviral drug discovery. J Med Chem. 2018;61:8734–8745.
   PubMed Web of Science ®Google Scholar
• Hua C, Ma Q, Zhu Y, et al. Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation. Signal Transduct Target Ther. 2021;6:318.
   PubMed Web of Science ®Google Scholar
• Koyama T, Platt D, Parida L. Variant analysis of SARS-CoV-2 genomes. Bull World Health Organ. 2020;98:495–504.
   PubMed Web of Science ®Google Scholar
• Brice DC, Diamond G. Antiviral activities of human host defense peptides. Curr Med Chem. 2020;27:1420–1443.
   PubMed Web of Science ®Google Scholar
• Ding J, Chou YY, Chang TL. Defensins in viral infections. J Innate Immun. 2009;1:413–420.
   PubMed Web of Science ®Google Scholar
• Keyaerts E, Li S, Vijgen L, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009;53:3416–3421.
   PubMed Web of Science ®Google Scholar
• Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23:300–302.
   PubMed Web of Science ®Google Scholar
• Falzarano D, Safronetz D, Prescott J, et al. Lack of protection against ebola virus from chloroquine in mice and hamsters. Emerg Infect Dis. 2015;21:1065–1067.
   PubMed Web of Science ®Google Scholar
• Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature. 2020;585(7826):584-587.
   Web of Science ®Google Scholar
• Kaptein SJF, Jacobs S, Langendries L, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci U S A. 2020;117:26955–26965.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven Protease inhibitor. Cell. 2020;181:271–280, e278.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76–84.
   PubMed Web of Science ®Google Scholar
• Breining P, Frølund AL, Højen JF, et al. Camostat mesylate against SARS-CoV-2 and COVID-19-rationale, dosing and safety. Basic Clin Pharmacol Toxicol. 2021;128:204–212.
   PubMed Web of Science ®Google Scholar
• Kadam RU, Juraszek J, Brandenburg B, et al. Potent peptidic fusion inhibitors of influenza virus. Science. 2017;358:496–502.
   PubMed Web of Science ®Google Scholar
• Zhao H, To KKW, Lam H, et al. Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. Nat Commun. 2021;12:1517.
   PubMed Web of Science ®Google Scholar
• Zhao H, Lu L, Peng Z, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2021;11(1):277–283.
   Web of Science ®Google Scholar
• Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009;16:265–273.
   PubMed Web of Science ®Google Scholar
• Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020;383:2030–2040.
   PubMed Web of Science ®Google Scholar
• Borba MGS, Almeida Val FF, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3:e208857.
   PubMed Web of Science ®Google Scholar
• Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis. 2011;11:677–683.
   PubMed Web of Science ®Google Scholar
• Kubo S, Tomozawa T, Kakuta M, et al. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother. 2010;54:1256–1264.
   PubMed Web of Science ®Google Scholar
• Balgi AD, Wang J, Cheng DYH, et al. Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay. PLoS One. 2013;8:e55271.
   PubMed Web of Science ®Google Scholar
• Finberg RW, Lanno R, Anderson D, et al. Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial. J Infect Dis. 2019;219:1026–1034.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Marty FM, Wolfe CR, et al. DAS181 treatment of severe lower respiratory tract parainfluenza virus infection in immunocompromised patients: a phase 2 randomized, placebo-controlled study. Clin Infect Dis. 2021;73(3):e773-e781.
   Web of Science ®Google Scholar
• An D, Li K, Rowe DK, et al. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine. Sci Adv. 2021;7(27):eabi5246.
   Web of Science ®Google Scholar
• Wu S, Huang J, Zhang Z, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021;21(12):1654-1664.
   Web of Science ®Google Scholar
• Zhao H, Chu H, Zhao X, et al. Novel residues in the PA protein of avian influenza H7N7 virus affect virulence in mammalian hosts. Virology. 2016;498:1–8.
   PubMed Web of Science ®Google Scholar
• Chen LL, Lu L, Choi CYK, et al. Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination. Clin Infect Dis. 2021.
   Web of Science ®Google Scholar
• To KK, Chan WM, Ip JD, et al. Unique SARS-CoV-2 clusters causing a large COVID-19 outbreak in Hong Kong. Clin Infect Dis. 2021;73(1):137-142.
   Google Scholar
• Lai KK, Cheung NN, Yang F, et al. Identification of novel fusion inhibitors of influenza A virus by chemical genetics. J Virol. 2015;90:2690–2701.
   PubMed Web of Science ®Google Scholar
• Zheng BJ, Chan K-W, Lin Y-P, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A. 2008;105:8091–8096.
   PubMed Web of Science ®Google Scholar